Logo

Biogen Requests a Preliminary Injunction in BPCIA Case Against Sandoz Proposed Biosimilar of Tysabri (natalizumab)

Share this
Biogen Requests a Preliminary Injunction in BPCIA Case Against Sandoz Proposed Biosimilar of Tysabri (natalizumab)

Biogen Requests a Preliminary Injunction in BPCIA Case Against Sandoz Proposed Biosimilar of Tysabri (natalizumab)

Shots:

  • In its BPCIA case against Sandoz regarding Sandoz's proposed Tysabri biosimilar, Biogen asks for a preliminary injunction (natalizumab). The joint stipulation of the parties and the proposed schedule for a motion for a preliminary injunction were addressed in a sealed order that the Court issued on Oct 20, 2022
  • A redacted version of Biogen's 107-page sealed complaint against Sandoz was recently released. Biogen claims that Sandoz's submission of an aBLA for PB006, a potential biosimilar of TYSABRI, violates 28 patents under the BPCIA
  • Biogen also claims that patents covering the production of Abs are being violated. Tysabri is a humanized mAb targeting alpha-4 integrin & is indicated for MS and CD

Ref: Big Molecule Watch | Image: Biogen 

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions